



Sheet 1 of 1.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. B45124	SERIAL NO. 09/581,976
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Dalemans, et al.	
		FILING DATE 20 June 2000	GROUP 1648

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No	
See	WO96/02555	1996	PCT	-	-		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

See	Wooldridge et al., "Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma", Blood, 89 (8), 1997, pgs 2994-2998
↓	Krieg et al., "CpG Motifs in Bacterial DNA Trigger Direct B-cell Activation", Nature, 374, 1995, pgs 546-549
↓	Chen et al., "Human Papillomavirus Type 16 Nucleoprotein E7 is a Tumor Rejection Antigen", Proc. Natl. Acad. Sci., 88, 1991, pgs 110-114
↓	Ullman et al., "Transforming Proteins of Human ", Medical Virology, 6, 1995, pgs 39-55
EXAMINER	DATE CONSIDERED
Nagun	01/13/2004
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

document1